Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 11/20 | 0.56 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 5/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613250 | 0.99 | MAP3K14 (0.57) | MAP3K14PIKFYVECHUKCLK1CDK5 | |
| SCHEMBL1613955 | 0.88 | MAP3K14 (0.57) | MAP3K14PIKFYVECHUKCLK1CDK5 | |
| SCHEMBL1612966 | 0.87 | MAP3K14 (0.56) | MAP3K14PIKFYVECHUKCLK1CDK5 | |
| SCHEMBL1612318 | 0.86 | MAP3K14 (0.55) | MAP3K14PIKFYVECHUKCLK1CDK5 | |
| SCHEMBL1614169 | 0.86 | CDK2 (0.46) | MAP3K14CHUKCCNT1CCNKCCNE1 | |
| SCHEMBL1614473 | 0.82 | MAP3K14 (0.70) | MAP3K14PIKFYVECHUKCLK1CDK5 | |
| SCHEMBL12743211 | 0.81 | MAP3K14 (0.50) | MAP3K14CLK1CDK5CDK5R1CCNT1 | |
| SCHEMBL1611663 | 0.81 | MAP3K14 (0.70) | MAP3K14PIKFYVECHUKCLK1CDK5 | |
| SCHEMBL1614224 | 0.80 | MAP3K14 (0.67) | MAP3K14PIKFYVECHUKCLK1CDK5 | |
| SCHEMBL12743223 | 0.80 | MAP3K14 (0.51) | MAP3K14CLK1CDK5CDK5R1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAP3K14 17/4885PIKFYVE 126/4885CHUK 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.